Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 57
- Registration Number
- NCT06046482
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination with Radiotherapy (RT) in Relapsed/refractory Follicular Lymphoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06043323
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase 2 Trial of Epcoritamab in Combination With Rituximab-mini CVP for Older Unfit/Frail Patients or Anthracycline-Ineligible Adult Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06045247
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06049134
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Spanish Decision Tool for Ovarian Cancer Maintenance Therapy
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 70
- Registration Number
- NCT06036810
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase 1, Open-Label, Sequential Cross-over, Bioavailability/Bioequivalence Study to Compare the Pharmacokinetics of Oral Cladribine With the Reference Listed Drug, Intravenous Cladribine
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06021600
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-29
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT06015295
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Phase Ib Trial of Eribulin in Combination with Irinotecan and Temozolamide in Children with Relapsed or Refractory Solid Tumors
Phase 1
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 48
- Registration Number
- NCT06006273
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma
Phase 1
Withdrawn
- Conditions
- Interventions
- First Posted Date
- 2023-08-23
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT06006286
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Peripheral Nerve Stimulation of Genicular Nerves Versus Conventional Therapy With Intra-articular Steroid Injection for Chronic Knee Pain: A Prospective, Randomized Pilot Study
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2023-08-22
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 45
- Registration Number
- NCT06004882
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2024. All Rights Reserved by MedPath